Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

Medical Device Regulatory Submissions in 2026: 510(k), De Novo, PMA, eSTAR, and FDA Approval Guide

Explore how FDA medical device submissions work across 510(k), De Novo, PMA, and eSTAR pathways. Learn how classification, predicate strategy, evidence planning, substantial equivalence, and quality documentation can support smoother premarket review and stronger regulatory readiness.
  • Blog, Medical Devices
Medical device premarket submission workflow showing eSTAR submission, predicate device comparison, substantial equivalence, and FDA premarket review.

US Pharmacopeia in 2026: USP–NF Standards, Monographs, General Chapters, and Pharmaceutical Compliance

Explore how USP-NF standards, monographs, General Chapters, and reference standards support pharmaceutical quality testing and GMP compliance. Learn which compendial requirements are mandatory, how teams manage updates, and what evidence laboratories should maintain for inspection readiness.
  • Blog, Quality Management System
Pharmaceutical quality laboratory applying USP monographs, reference standards, analytical testing, and GMP compliance controls.

BMS Bets $2.3B on Texas; One Campus Spans Three Drug Modalities

Bristol Myers Squibb plans to invest $2.3 billion in a new manufacturing campus at Generation Park in Houston, Texas. The company says the site will support next-generation medicines, create nearly 500 skilled jobs and expand U.S. production capacity. More importantly,
  • News
BMS Bets $2.3B on Texas; One Campus Spans Three Drug Modalities

USP 797 Compliance in 2026: Sterile Compounding Requirements, Cleanrooms, Training, and Inspection Readiness

Explore current USP 797 requirements for sterile compounding, cleanroom controls, personnel training, environmental monitoring, aseptic technique, and beyond-use dates. Learn how pharmacy and quality teams can strengthen inspection readiness and maintain reliable control over compounded sterile preparations.
  • Blog, Validation and Qualification
Sterile compounding technician performing aseptic technique inside a controlled cleanroom with environmental monitoring systems.

AI Spending Is Surging, Results Aren’t; Workforce Qualification May Explain Pharma’s ROI Gap

Pharma companies continue to increase AI investment, but expected gains in development timelines and success rates remain limited. In an August 10, 2026 analysis for Pharmaceutical Technology, Brian Drapeau argues that workforce qualification may be the missing link. The issue
  • News
AI Spending Is Surging, Results Aren’t; Workforce Qualification May Explain Pharma’s ROI Gap

EDQM Adds Three Immunoglobulin Tests; QC Labs Must Prepare by July 2027

The EDQM has introduced Ph. Eur. General Chapter 2.6.42 for procoagulant activity testing in human immunoglobulin preparations. EDQM announced the change in Strasbourg on 10 August 2026. The chapter will appear in Ph. Eur. Issue 13.3 in October and take
  • News
EDQM Adds Three Immunoglobulin Tests; QC Labs Must Prepare by July 2027

ISO 9000 in Pharma Industry in 2026: QMS Principles, ISO 9001, GMP Alignment and Implementation Guide

Explore how ISO 9000 principles support pharmaceutical quality systems, strengthen GMP compliance, and connect with ISO 9001 and ICH Q10. Learn how quality teams can apply process-based management, risk-based decisions, and continual improvement to build inspection-ready operations.
  • Blog, Quality Management System
Pharmaceutical quality management system showing GMP compliance, process approach, quality controls, and continual improvement across regulated manufacturing operations.

Thermo Fisher Sees 15–20% India Customer Growth; Global-Standard Labs Drive Demand

Thermo Fisher Scientific expects its customer base in India to grow by 15% to 20% over the next five years as biopharma research and manufacturing expand across the country. The company also forecasts continued double-digit growth, driven by rising demand
  • News
Thermo Fisher Sees 15–20% India Customer Growth; Global-Standard Labs Drive Demand